Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment

12 Jul 2016 12:36

ONZIMA VENTURES PLC - Investment

ONZIMA VENTURES PLC - Investment

PR Newswire

London, July 12

Onzima Ventures PLC

("Onzima" or the "Company")

Investment in Kolar Gold Limited

Onzima is pleased to announce that it has participated in the conditional fundraising by Kolar Gold Limited (LON: KGLD) (“Kolar Gold”).

Highlights:

Transaction subject to Kolar Gold shareholder approval at Extraordinary General Meeting to be held on 27 July 2016; Onzima to invest £30,000 in cash to acquire 2,727,273 new ordinary shares in Kolar Gold at a price of 1.1p per new ordinary share (equivalent to approximately 1.4% of the enlarged issued share capital of Kolar Gold); Onzima to also receive 2,727,273 warrants to acquire new ordinary shares in Kolar Gold at an exercise price of 2.2p per new ordinary share with 30 month life; Board restructuring proposed at Kolar Gold – Cameron Parry, currently CEO of Metal Tiger plc to take up the position of CEO of Kolar Gold, subject to the passing of the resolutions at the Kolar Gold GM to be held on 27 July 2016. Luke Cairns, non-executive Director of Onzima ventures plc, to join as the other Executive Director of Kolar Gold. Harvinder Hungin to remain Non-Executive Chairman, Steven Oke to remain Non-Executive Director and Vaidyanathan Sivakumar to step down as Non-executive director; and New board of Kolar Gold plan an immediate operational review covering existing exploration interests and various acquisition opportunities.

Gavin Burnell, Chief Executive Officer of Onzima commented “We are pleased to support the fundraising, board and strategy changes at Kolar Gold which provides Onzima with good upside exposure for its investment”.

For further information please contact:

Onzima Ventures PLC Tel: +44 (0) 1732 366 561Gavin Burnell, Luke Cairns

Nominated AdviserCairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900 Sandy Jamieson, Liam Murray

BrokerPeterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930 Guy Miller, Lucy Williams

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.

Date   Source Headline
29th Apr 202410:59 amRNSPosting of Annual Report & Notice of AGM
26th Apr 20247:00 amRNSN4 Pharma Webinar on SRI Collaboration
25th Apr 20247:38 amRNSCollaboration Agreement with SRI International Inc
23rd Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSOral Delivery Update
4th Mar 20243:13 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSin-vitro siRNA update
19th Jan 20247:00 amRNSPatent Grant
18th Jan 202410:15 amRNSHolding(s) in Company
16th Jan 20247:00 amRNSNanogenics Update
8th Jan 20244:24 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSAAV Viral Vector Update
18th Dec 20237:00 amRNSOral Delivery Update
7th Dec 202311:28 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSNuvec® R&D and Strategy Update
30th Nov 20239:00 amRNSN4 Pharma Launches New Interactive Investor Hub
31st Oct 20237:00 amRNSTotal Voting Rights
9th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 20238:15 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSInvestor Presentation
28th Sep 20237:00 amRNSAcquisition of Controlling Interest in Nanogenics
12th Sep 20237:00 amRNSInterim Results
25th Jul 20237:00 amRNSPatent Grant and Board Change
27th Jun 20237:00 amRNSGrant Award for Professor Chengzhong Yu
25th Apr 20237:00 amRNSsiRNA update
18th Apr 20237:00 amRNSsiRNA update
3rd Apr 20232:11 pmRNSResult of AGM
9th Mar 20237:00 amRNSPosting of Annual Report & Notice of AGM
9th Mar 20237:00 amRNSFinal Results
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSOral application update
30th Nov 20225:28 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20222:49 pmRNSHolding(s) in Company
22nd Nov 202210:50 amRNSResult of Broker Offer and Total Voting Rights
18th Nov 20227:01 amRNSBroker Offer to raise a maximum of £1 million
18th Nov 20227:00 amRNSPlacing to raise £1million and Broker Offer
1st Nov 20227:00 amRNSPatent filing update
4th Oct 20227:00 amRNSDouble siRNA Testing Update
29th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOperational Update
15th Jul 20227:00 amRNSWork Programme Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.